Cannabis Bioscience International Holdings (CBIH) Introduces Intranasal Nanoemulsion Platform for Alzheimer's Disease Research

CBIH's Multi-Pathway Strategy for Alzheimer's Disease Research

CBIH’s newly introduced intranasal nanoemulsion platform marks a strategic evolution in cannabinoid-based neurodegenerative disease research. Instead of focusing on isolated biological mechanisms, this platform facilitates simultaneous evaluation of selected neuroactive compounds across multiple pathways. This reflects CBIH’s recognition that Alzheimer's disease’s complex and progressive nature demands a broader therapeutic approach beyond traditional single-target drug development.

The choice of intranasal delivery is a critical innovation, designed to enhance the neurological relevance of cannabinoid-based and natural compounds by potentially improving bioavailability and targeting affected brain regions more effectively. Dr. Rosangel Andrades, M.D., Director of Research and Development at CBIH, emphasized that the platform is "designed to bring selected cannabinoid-based and natural compounds into a neurologically relevant formulation and explore their potential across multiple pathways."

Alzheimer's Disease Impact and Unmet Needs

CBIH situates its platform development within the broader context of Alzheimer's disease epidemiology and economic burden in North America. Approximately 7.4 million Americans aged 65 and older were estimated to be living with Alzheimer's dementia in 2026, with projections indicating an increase to 13.8 million by 2060, nearly doubling over 34 years.

The financial impact is substantial, with Alzheimer's and related dementias accounting for an estimated $409 billion in health and long-term care costs in 2026. This includes direct medical expenses, long-term care, caregiving, healthcare utilization, and broader socioeconomic effects, underscoring the urgent need for innovative therapeutic solutions.

Advancing Cannabinoid Science in Neurological Research

CBIH’s platform development is grounded in the potential of cannabinoid-based compounds as neuroactive agents in Alzheimer's disease research. The company stresses that rigorous scientific application of cannabinoid science may unlock new mechanisms beneficial for neurodegenerative conditions. The intranasal delivery method is specifically chosen to maximize neurological impact, highlighting the importance of administration routes in therapeutic effectiveness.

The research strategy involves examining cannabinoid and natural compounds through "a new neurological lens," signaling a departure from existing paradigms. Dr. Andrades stated the company’s commitment to "question[ing] established assumptions, and never stop searching for answers that deepen our understanding" of Alzheimer's disease, positioning this platform as a key element in redefining cannabinoid science’s role in neurodegenerative research.

Intranasal Nanoemulsion Technology Overview

CBIH’s platform leverages intranasal nanoemulsion technology, a method known to enhance drug solubility, stability, and penetration into the nervous system. Although detailed formulation specifics were not disclosed, nanoemulsions are recognized for their pharmaceutical applications and their potential to improve delivery of neuroactive compounds via the intranasal route.

The intranasal administration offers advantages by bypassing certain absorption barriers and achieving higher localized concentrations in the brain compared to other delivery methods. Combining nanoemulsion technology with intranasal delivery, CBIH aims to maximize the neurological relevance and therapeutic potential of the cannabinoid-based and natural compounds under study.

Scientific Leadership and Direction

Dr. Rosangel Andrades, M.D., CBIH’s Director of Research and Development, leads the scientific narrative on the platform’s development and rationale. She highlights that Alzheimer's disease "does not follow a single biological pathway," forming the conceptual basis for the company's multi-pathway research approach and the platform’s design as a response to limitations in traditional single-target therapies.

The announcement does not elaborate on the broader research team, partnerships, or external scientific collaborations supporting the platform. Investors interested in further details about the scientific infrastructure may consult CBIH’s public filings and disclosures.

Positioning in Neurodegenerative Disease Innovation

CBIH positions itself at the forefront of cannabinoid science intersecting with neurodegenerative disease research. The company frames its initiative as not only product development but also as a commitment to advancing scientific understanding of how cannabinoid-based compounds may address Alzheimer's complex pathology. This approach aligns with the urgent need for effective treatments in a disease area with significant unmet medical demand.

The announcement also emphasizes the human impact of Alzheimer's, focusing on preserving "memories, relationships, and identities," which resonates with investors, patients, caregivers, and healthcare stakeholders invested in therapeutic advancements.

Development Timeline and Clinical Considerations

The release does not provide a detailed timeline, preclinical or clinical study plans, regulatory strategies, or milestone projections for the intranasal cannabinoid platform. While emphasizing scientific rigor, it does not specify the current development stage or regulatory interactions with agencies such as Health Canada or the FDA.

Forward-looking statements acknowledge the inherent uncertainty in drug development, noting that "the path toward meaningful breakthroughs is long and uncertain." No commitments on development timelines, regulatory pathways, or success probabilities are provided.

Forward-Looking Statements and Risk Factors

CBIH includes a disclaimer noting that terms like "believe," "expect," "should," "intend," "estimate," and "projects" indicate forward-looking statements subject to risks and uncertainties. The company disclaims any obligation to update these statements based on new information or future events.

Investors are directed to CBIH’s filings on www.OTCmarkets.com for detailed risk disclosures. Trading under the OTC ticker CBIH, the company’s securities typically involve higher regulatory uncertainty, lower liquidity, and fewer disclosure requirements compared to exchange-listed firms. The announcement does not specify regulatory filings or reporting practices.

Investor Resources and Market Impact

For additional information on CBIH’s Alzheimer's research platform, corporate strategy, financial status, or operations, investors can visit www.cbih.net and follow the company’s X (formerly Twitter) and Instagram accounts. Contact details are provided, though this announcement serves as the primary public disclosure of the intranasal cannabinoid platform to date.

The immediate effect on CBIH’s share price is not evident from public data. Investors should consult current market information to assess how the announcement may have influenced trading activity and valuation. Market response will depend on factors including perceived platform potential, investor interest in cannabinoid biotech, and broader conditions affecting small-cap OTC stocks.